Literature DB >> 31736082

Distinct trajectories of long-term symptom severity in pediatric obsessive-compulsive disorder during and after stepped-care treatment.

Sanne Jensen1, Davíð R M A Højgaard1, Katja A Hybel1, Erik Lykke Mortensen2, Gudmundur Skarphedinsson3, Karin Melin4,5, Tord Ivarsson4,6, Judith Becker Nissen1, Bernhard Weidle6, Robert Valderhaug6, Nor Christian Torp7, Kitty Dahl8, Scott Compton9, Per Hove Thomsen1.   

Abstract

BACKGROUND: First-line treatments for pediatric obsessive-compulsive disorder (OCD) include exposure-based cognitive-behavioral therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs). No studies have thus far identified distinct classes and associated predictors of long-term symptom severity during and after treatment. Yet, these could form the basis for more personalized treatment in pediatric OCD.
METHOD: The study included 269 OCD patients aged 7-17 years from the Nordic Long-term OCD Treatment Study (NordLOTS). All participants received stepped-care treatment starting with 14 weekly sessions of manualized CBT. Nonresponders were randomized to either prolonged CBT or SSRIs. Symptom severity was assessed using the Children's Yale-Brown Obsessive-Compulsive Scale at seven time points from pre- to post-treatment and over a three-year follow-up. Latent class growth analysis (LCGA) was performed to identify latent classes of symptom severity trajectories. Univariate and multivariate analyses were used to detect differences between classes and identify predictors of trajectory class membership including several clinical and demographic variables. TRIAL REGISTRY: Nordic Long-term Obsessive-Compulsive Disorder (OCD) Treatment Study; www.controlled-trials.com; ISRCTN66385119.
RESULTS: Three LCGA classes were identified: (a) acute, sustained responders (54.6%); (b) slow, continued responders (23.4%); and (c) limited long-term responders (21.9%). Class membership was predicted by distinct baseline characteristics pertaining to age, symptom severity, contamination/cleaning and anxiety symptoms.
CONCLUSIONS: The LCGA suggests three distinct trajectory classes of long-term symptom severity during and after treatment in pediatric OCD with different clinical profiles at pretreatment. The results point to required clinical attention for adolescent patients with contamination/cleaning and anxiety symptoms who do not show convincing responses to first-line treatment even though they may have reached the established cutoff for treatment response.
© 2019 Association for Child and Adolescent Mental Health.

Entities:  

Keywords:  Obsessive-compulsive disorder; children and adolescents; latent class growth analysis; longitudinal study; outcome predictors; stepped-care treatment; trajectories

Year:  2019        PMID: 31736082     DOI: 10.1111/jcpp.13155

Source DB:  PubMed          Journal:  J Child Psychol Psychiatry        ISSN: 0021-9630            Impact factor:   8.982


  3 in total

1.  Symptom Trajectories of Early Responders and Remitters among Youth with OCD.

Authors:  Megan Rech; Saira Weinzimmer; Daniel Geller; Joseph F McGuire; Sophie C Schneider; Kevin C Patyk; Alessandro S De Nadai; Sandra C Cepeda; Brent J Small; Tanya K Murphy; Sabine Wilhelm; Eric A Storch
Journal:  J Obsessive Compuls Relat Disord       Date:  2020-08-29       Impact factor: 2.236

2.  Quality of life in pediatric patients with obsessive-compulsive disorder during and 3 years after stepped-care treatment.

Authors:  Sanne Jensen; Katja A Hybel; Davíð R M A Højgaard; Judith Becker Nissen; Bernhard Weidle; Tord Ivarsson; Gudmundur Skarphedinsson; Karin Melin; Nor Christian Torp; Anders Helles Carlsen; Erik Lykke Mortensen; Fabian Lenhard; Scott Compton; Per Hove Thomsen
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-04-21       Impact factor: 5.349

Review 3.  Scoping review of stepped care interventions for mental health and substance use service delivery to youth and young adults.

Authors:  Mai Berger; Saranee Fernando; AnnMarie Churchill; Peter Cornish; Joanna Henderson; Jai Shah; Karen Tee; Amy Salmon
Journal:  Early Interv Psychiatry       Date:  2021-05-21       Impact factor: 2.721

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.